MINNEAPOLIS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that the American Medical Association (AMA) CPT Editorial Panel has approved the establishment of a new set of Current Procedural Terminology (CPT) codes that accurately describe and include the Inspire V system. The new Category I codes are scheduled to take effect on January 1, 2028.
"This new CPT code language addresses the implantation of a single lead and an implantable pulse generator (IPG) including our recently launched Inspire V system," said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. "We appreciate the AMA creating dedicated codes that will create a clearer, more consistent path for coding and reimbursement, which we expect will reduce administrative burden for hospitals and physicians and support continued growth in patient access to Inspire therapy. The application received broad society support with special thanks to the American Academy of Otolaryngology-Head and the Neck Surgery (AAO-HNS), the American Academy of Sleep Medicine (AASM) and the International Surgical Sleep Society (ISSS) for their support addressing the need to act now to provide a permanent coding solution for the Inspire V system and other single lead hypoglossal nerve stimulation IPG therapies."
With the new codes created, the Centers for Medicare & Medicaid Services (CMS) will conduct its standard process to determine the value for each new CPT code, which determines the payments for that service under Medicare. CMS typically requests the AMA Relative Value Scale Update Committee (RUC) to review specific codes and evaluate whether physician time, work and expenses for related services have changed over time.
Specialty societies, such as the AAO-HNS, may survey their members and make recommendations to the RUC based on the output from the rigorous methodology for these surveys. These surveys would collect information regarding physician work including both time and complexity, practice expenses including clinical staff and any required supplies and equipment, and liability insurance. Sufficient physicians are surveyed to ensure accuracy of data collected.
After collecting and reviewing the data, the RUC recommendation is provided to CMS who we expect would publish their proposed valuation in July 2027 with final valuations published in November 2027.
The new Category I CPT codes reflect a growing body of clinical evidence supporting therapies like Inspire's closed-loop implantable device, Inspire V, which is designed to work with a patient's natural breathing to help keep the airway open during sleep. With more than 140,000 patients treated and over a decade of clinical experience, Inspire is a well-established leader in the treatment of OSA.
About Inspire Medical Systems
Inspire Medical Systems is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first FDA, EU MDR, and PDMA-approved neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the anticipated implementation and effective date of the newly approved CPTcodes and the potential impact of such codes on coding, reimbursement, patient access, and adoption of Inspire therapy. Forward-looking statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions.
These forward-looking statements are based on management's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these risks and uncertainties can be found under the caption "Risk Factors" in Inspire Medical Systems, Inc.'s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.
Any forward-looking statements contained in this press release speak only as of the date hereof. Inspire undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Investor Contact
Brian Johnston or Louisa Smith
Gilmartin Group, LLC
IR@inspiresleep.com
